Autoimmunity in systemic sclerosis: Current concepts

Current Rheumatology Reports

Volumn 9, Issue 2, 2007, Pages 165-172

  Boin, Francesco ^b   Rosen, Antony ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AUTOANTIBODY; AUTOANTIGEN;

AUTOIMMUNITY; B LYMPHOCYTE; BLOOD VESSEL INJURY; CELL FUNCTION; HUMAN; HUMORAL IMMUNITY; IN VIVO STUDY; LYMPHOCYTE; NONHUMAN; REVIEW; SYSTEMIC SCLEROSIS; T LYMPHOCYTE;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HUMANS; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTES;

EID: 34250622113     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0012-3     Document Type: Review

References (60)

1. Wigley FM, Hummers LK: Clinical features of systemic sclerosis. In Rheumatology, 3rd edition. Edited by Hochberg MC, Silman AJ, Smolen JS, et al. St. Louis: Mosby; 2003:1463-1480.
2. Harris ML, Rosen A: Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 2003, 15:778-784.
3. Hu PQ, Fertig N, Medsger TA Jr, et al.: Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003, 48:1363-1373.
4. Zhou X, Tan F, Milewicz DM, et al.: Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the "scleroderma phenotype." J Immunol 2005, 175:4555-4560. Interestingly, anti-FBN1 antibodies can activate and induce a profibrotic phenotype in dermal fibroblasts, through a TGF-β-mediated pathway. However, other groups failed to detect these autoantibodies in SSc patients.
5. Baroni SS, Santillo M, Bevilacqua F, et al.: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667-2676. This is the first published report describing the presence in SSc patients of PDGFR-stimulating antibodies, which can increase synthetic activity of fibroblasts and promote their differentiation into myofibroblasts. This is of great interest, because PDGF function has been linked to aberrant tissue fibrogenesis as well as intimal hyperplasia in different obliterative vascular disorders. If confirmed in larger studies, these data may provide the rationale for treatment strategies targeted to direct pathogenetic mechanisms in SSc.
6. Henault J, Robitaille G, Senecal JL, et al.: DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 2006, 54:963-973. This study shows that topo-1 can be recognized directly on the surface of fibroblasts by anti-topo-1 antibodies and thus activate monocytes. These findings may suggest a direct role of topo-1-specific immune response in the initiation and/or amplification of the local inflammatory and fibrotic damage in SSc.
7. Abraham DJ, Varga J: Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005, 26:587-595.
8. Chizzolini C, Raschi E, Rezzonico R, et al.: Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002, 46:1602-1613.
9. Kaneko Y, Nimmerjahn F, Ravetch JV: Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313:670-673.
10. Kaartinen V, Warburton D: Fibrillin controls TGF-beta activation. Nat Genet 2003, 33:331-332.
11. Dietz HC, Pyeritz RE: Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Hum Mol Genet 1995, 4 Spec No:1799-1809.
12. Tan FK, Arnett FC, Antohi S, et al.: Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol 1999, 163:1066-1072.
13. Murai C, Saito S, Kasturi KN, et al.: Spontaneous occurrence of anti-fibrillin-1 autoantibodies in tight-skin mice. Autoimmunity 1998, 28:151-155.
14. Brinckmann J, Hunzelmann N, El-Hallous E, et al.: Absence of autoantibodies against correctly folded recombinant fibrillin-1 protein in systemic sclerosis patients. Arthritis Res Ther 2005, 7:R1221-1226.
15. Vincent A, Leite MI: Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 2005, 18:519-525.
16. Schermuly RT, Dony E, Ghofrani HA, et al.: Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005, 115:2811-2821.
17. Gay S, Jones RE Jr, Huang GQ, Gay RE: Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 1989, 92:301-303.
18. Yamakage A, Kikuchi K, Smith EA, et al.: Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 1992, 175:1227- 1234.
19. Abdollahi A, Li M, Ping G, et al.: Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005, 201:925-935.
20. Laplante P, Raymond MA, Gagnon G, et al.: Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis. J Immunol 2005, 174:5740-5749.
21. Worda M, Sgonc R, Dietrich H, et al.: In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum 2003, 48:2605-2614.
22. Prescott RJ, Freemont AJ, Jones CJ, et al.: Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992, 166:255-263.
23. Harrison NK, Myers AR, Corrin B, et al.: Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991, 144:706-713.
24. Mavalia C, Scaletti C, Romagnani P, et al.: Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997, 151:1751-1758.
25. Lee CG, Homer RJ, Zhu Z, et al.: Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001, 194:809-821.
26. Tsuji-Yamada J, Nakazawa M, Minami M, et al.: Increased frequency of interleukin 4 producing CD4+ and CD8+ cells in peripheral blood from patients with systemic sclerosis. J Rheumatol 2001, 28:1252-1258.
27. Luzina IG, Atamas SP, Wise R, et al.: Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. Arthritis Rheum 2003, 48:2262-2274.
28. Hamilton RF Jr, Parsley E, Holian A: Alveolar macrophages from systemic sclerosis patients: evidence for IL-4-mediated phenotype changes. Am J Physiol Lung Cell Mol Physiol 2004, 286:L1202-1209.
29. Sgonc R, Gruschwitz MS, Dietrich H, et al.: Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996, 98:785-792.
30. Bobik A: Transforming growth factor-betas and vascular disorders. Arterioscler Thromb Vasc Biol 2006, 26:1712-1720.
31. Choy JC, Cruz RP, Kerjner A, et al.: Granzyme B induces endothelial cell apoptosis and contributes to the development of transplant vascular disease. Am J Transplant 2005, 5:494-499. This work confirms that cytotoxic T cells can cause endothelial damage directly through their granule content (GrB) and thus contribute to chronic allograft vasculopathy. A similar pathway can be important for SSc vascular disease.
32. Buzza MS, Zamurs L, Sun J, et al.: Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J Biol Chem 2005, 280:23549-23558.
33. Kahaleh MB, Fan PS: Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol 1997, 83:32-40.
34. Casciola-Rosen L, Andrade F, Ulanet D, et al.: Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999, 190:815-826.
35. Del Galdo F, Artlett CM, Jimenez SA: The role of allograft inflammatory factor 1 in systemic sclerosis. Curr Opin Rheumatol 2006, 18:588-593.
36. Utans U, Arceci RJ, Yamashita Y, et al.: Cloning and characterization of allograft inflammatory factor-1: a novel macrophage factor identified in rat cardiac allografts with chronic rejection. J Clin Invest 1995, 95:2954-2962.
37. Kelemen SE, Autieri MV: Expression of allograft inflammatory factor-1 in T lymphocytes: a role in T-lymphocyte activation and proliferative arteriopathies. Am J Pathol 2005, 167:619-626.
38. Tian Y, Kelemen SE, Autieri MV: Inhibition of AIF-1 expression by constitutive siRNA expression reduces macrophage migration, proliferation, and signal transduction initiated by atherogenic stimuli. Am J Physiol Cell Physiol 2006, 290:0083-1091.
39. Tan FK, Zhou X, Mayes MD, et al.: Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006, 45:694-702.
40. Del Galdo F, Maul GG, Jimenez SA, et al.: Expression of allograft inflammatory factor 1 in tissues from patients with systemic sclerosis and in vitro differential expression of its isoforms in response to transforming growth factor beta. Arthritis Rheum 2006, 54:2616-2625. This is the first study reporting increased expression of AIF-1 in ECs, macrophages, and T lymphocytes infiltrating vessel walls of lesional skin and lung biopsies in SSc patients. Different AIF-1 isoforms are induced by polarized cytokines such as TGF-β or IFN-γ. AIF-1 proinflammatory properties and its ability to promote vascular smooth muscle cells migration/proliferation may be relevant in the pathogenesis of SSc vasculopathy.
41. Sakkas LI, Chikanza IC, Platsoucas CD: Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2006, 2:679-685.
42. Sakkas LI, Xu B, Artlett CM, et al.: Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002, 168:3649-3659.
43. Yurovsky VV, Wigley FM, Wise RA, et al.: Skewing of the CD8+ T-cell repertoire in the lungs of patients with systemic sclerosis. Hum Immunol 1996, 48:84-97.
44. Dereure O, Gubler B, Bessis D, et al.: The presence of dominant T-cell clones in peripheral blood of patients with collagen vascular disorders: a prospective study of 97 cases. Br J Dermatol 2006, 154:445-449.
45. De Palma R, Del Galdo F, Lupoli S, et al.: Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin. Clin Exp Immunol 2006, 144:169-176.
46. Winek J, Mueller A, Csernok E, et al.: Frequency of proteinase 3 (PR3)-specific autoreactive T cells determined by cytokine flow cytometry in Wegener's granulomatosis. J Autoimmun 2004, 22:79-85.
47. Arnett FC: HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol 1995, 12:107-128.
48. Vazquez-Abad D, Russell C, Cusick SM, et al.: Longitudinal study of anticentromere and antitopoisomerase-I isotypes. Clin Immunol Immunopathol 1995, 74:257-270.
49. Kuwana M, Medsger TA Jr, Wright TM: T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors. J Clin Invest 1995, 96:586-596.
50. Rands AL, Whyte J, Cox B, et al.: MHC class II associations with autoantibody and T cell immune responses to the scleroderma autoantigen topoisomerase I. J Autoimmun 2000, 15:451-458.
51. Veeraraghavan S, Renzoni E, Jeal H, et al.: Mapping of the immunodominant T cell epitopes of the protein topoisomerase I. Ann Rheum Dis 2004, 63:982-987.
52. Hu PQ, Oppenheim JJ, Medsger TA Jr, et al.: T cell lines from systemic sclerosis patients and healthy controls recognize multiple epitopes on DNA topoisomerase I. J Autoimmun 2006, 26:258-267.
53. Kern F, LiPira G, Gratama JW, et al.: Measuring Ag-specific immune responses: understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer. Trends Immunol 2005, 26:477-484. This excellent review examines newer technologies now available to measure and characterize autoreactive T cells. These technologies are mostly single-cell based assays catching different aspects of the antigen-specific T-cell response.
54. Boin F, Wigley FM, Schneck JP, et al.: Evaluation of topoisomerase-1-specific CD8+ T-cell response in systemic sclerosis. Ann N Y Acad Sci 2005, 1062:137-145. This limited study describes a new small-volume ex vivo assay for detection of autoantigen-specific CD8+ T cells in SSc patients. This single-cell-based approach presents several important advantages: rapid ex-vivo application, testing of target tissue-specific specimens (eg, BAL fluid), and possible correlation of quantitative and functional data with relevant SSc clinical features.
55. Davidson A, Diamond B: Autoimmune diseases. N Engl J Med 2001, 345:340-350.
56. Sato S, Fujimoto M, Hasegawa M, et al.: Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004, 50:1918-1927.
57. Tedder TF, Poe JC, Fujimoto M, et al.: The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system. Curr Dir Autoimmun 2005, 8:55-90.
58. Matsushita T, Hasegawa M, Yanaba K, et al.: Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006, 54:192-201.
59. /+ newborn mice, suggesting that B-cell abnormalities may be relevant during early phases of SSc pathogenesis and that B-cell depletion therapy may be potentially helpful at the time of SSc disease onset.
60. Nishijima C, Hayakawa I, Matsushita T, et al.: Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 2004, 138:357-363.